PFNX - Pfenex to Announce Second Quarter 2019 Financial Results on August 8
SAN DIEGO, July 25, 2019 (GLOBE NEWSWIRE) -- Pfenex Inc. (NYSE American: PFNX), a clinical-stage development and licensing biotechnology company focused on leveraging its Pf?nex Expression Technology® to improve protein therapies for unmet patient needs, today announced that it will report its financial results for the second quarter and six months ended June 30, 2019, after the market close on Thursday, August 8, 2019, and will host a conference call and webcast at 4:30 PM Eastern Time.
| Conference Call & Webcast |
| Thursday, August 8th @ 4:30pm Eastern Time/1:30pm Pacific Time |
| Domestic: |
| 866-376-8058 |
| International: |
| 412-542-4131 |
| Webcast: |
| https://www.webcaster4.com/Webcast/Page/1061/31219 |
| Replays, Available Through August 15th: |
| Domestic: |
| 877-344-7529 |
| International: |
| 412-317-0088 |
| Replay Access Code: |
| 10133889 |
About Pfenex Inc.
Pfenex is a clinical-stage development and licensing biotechnology company focused on leveraging its Pf?nex Expression Technology® to develop and improve protein therapies for unmet patient needs. Using the patented Pf?nex Expression Technology platform, Pfenex has created an advanced pipeline of therapeutic equivalents, vaccines, biologics and biosimilars. Pfenex also uses its Pf?nex Expression Technology platform to produce CRM197, a diphtheria toxoid carrier protein used in prophylactic and therapeutic vaccines. Pfenex’s lead product candidate is PF708, a therapeutic equivalent candidate to Forteo® (teriparatide) for the treatment of osteoporosis. In addition, Pfenex is developing hematology/oncology products, including PF743, a recombinant crisantaspase, and PF745, a recombinant crisantaspase with half-life extension technology, in collaboration with Jazz Pharmaceuticals.
Pfenex investors and others should note that Pfenex announces material information to the public about Pfenex through a variety of means, including its website (http://www.pfenex.com/), its investor relations website (http://pfenex.investorroom.com/), press releases, SEC filings, public conference calls, corporate Twitter account (https://twitter.com/pfenex), Facebook page (https://www.facebook.com/Pfenex-Inc-105908276167776/timeline/), and LinkedIn page (https://www.linkedin.com/company/pfenex-inc) in order to achieve broad, non-exclusionary distribution of information to the public and to comply with its disclosure obligations under Regulation FD. Pfenex encourages its investors and others to monitor and review the information Pfenex makes public in these locations as such information could be deemed to be material information. Please note that this list may be updated from time to time.
Company Contact:
Susan A. Knudson
Chief Financial Officer
(858) 352-4324
sknudson@pfenex.com